Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients

Not Applicable

Completed

Interventions: Diagnostic Test: ENT exam
Diagnostic Test: Olfactometry
Diagnostic Test: Brain MRI

Brief Summary: Olfactory and gustatory disorders are prevalent symptoms in European COVID-19 patients. This study aimed to detect these disturbances among positive COVID-19 patients (symptom not initially highlighted by the patient and not sought by caregivers) in order to allow early management of olfactory and gustatory dysfunction.

Detailed Description: Several medical teams have recently shown that disturbances of smell and taste are common and can be a precursor and even an isolated sign of COVID-19 involvement. Preliminary results suggest the presence of clinical MRI abnormalities, particularly in the olfactory bulbs in anosmic patients with COVID-19.

Anosmia and taste disturbance are early warning signs that could be important in improving the detection and diagnosis of COVID-19, and also in monitoring disease. In addition, disturbances in smell and taste could be an aid in establishing the prognosis of the clinical course of the viral disease. The question of olfactory recovery is also fundamental. To date, we do not know the possibilities of recovery from COVID-19 post viral anosmia. ENT exams, olfactometry and MRI are proposed to study these phenomena.

Recruitment & Eligibility

Inclusion Criteria

Patient aged 18 or over
Patient with or without a sense of smell diagnosed with a positive COVID-19 PCR test by nasopharyngeal swab in one of the investigation centers
Patient who has already undergone cerebral MRI and olfactometry, as part of their routine care, within 3 days of being diagnosed with COVID-19+ or who agrees to undergo cerebral MRI and olfactometry within 3 days of being diagnosed with COVID-19+.
Patient who signed a consent form
Patient being affiliated to a Health Insurance plan

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
anosmic or normosmic COVID-19 patients	Olfactometry	Patients will undergo ENT exams, olfactometry and MRI.
anosmic or normosmic COVID-19 patients	Brain MRI	Patients will undergo ENT exams, olfactometry and MRI.
anosmic or normosmic COVID-19 patients	ENT exam	Patients will undergo ENT exams, olfactometry and MRI.

Primary Outcome Measures

Name	Time	Method
To compare the qualitative and quantitative morphological abnormalities of the olfactory bulb detected by MRI on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients.	initial examination	Intensity ratio calculated between average signals of the olfactory bulb and the frontal white matter on a 3-Tesla MRI scanner.
To compare the result of the olfactometry (Sniffin' test) on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients.	initial examination	Sniffin' test score (T threshold score, D discrimination score, I identification score).

Secondary Outcome Measures

Name	Time	Method
To compare the result of the olfactometry (Sniffin' test) on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients.	initial examination, 6 week to 2 months, 6 to 9 months	Sniffin' test score (T threshold score, D discrimination score, I identification score).
Longitudinal evaluation of qualitative and quantitative abnormalities of olfactory bulbs on MRI in in COVID-19 anosmic patient at initial examination, between 6 weeks and 2 months and between 6 and 9 months.	initial examination, 6 week to 2 months, 6 to 9 months	Intensity ratio calculated between average signals of the olfactory bulb and the frontal white matter on a 3-Tesla MRI scanner at initial examination, between 6 weeks and 2 months and between 6 and 9 months.

Locations (2): Hopital Raymond Poincare
🇫🇷
Garches, France
Hopital Foch
🇫🇷
Suresnes, Ile-de-France, France